Case Study

Astra + Zeneca (A): "Merger of equals"

12 pages
October 2002
Reference: IMD-3-1088

Consolidations and paradigm shifts in the pharmaceutical industry in the 1990s induced Astra and Zeneca to review potential merger partners. Both companies were confident of surviving on their own, banking on organic growth. However, escalating costs in R&D and sales and marketing, patent expiries, benefits of scale, and pressure on prices made this increasingly difficult to sustain. After 6 months of discussion, Astra and Zeneca announced a “merger of equals” in December 1998. This first part of a two-part case series looks at some of the “black box issues,” how they were negotiated to ensure that this was indeed a merger of equals and the final outcome of the negotiations.

Keywords
Merger of Equals
Settings
World/global
September 1998
Type
Field Research
Copyright
© 2002
Available Languages
English
Related material
Video
Case clearing houses
Contact

Research Information & Knowledge Hub for additional information on IMD publications

Discover our latest research
IMD's faculty and research teams publish articles, case studies, books and reports on a wide range of topics